Yp. Dragan et al., STUDIES OF TAMOXIFEN AS A PROMOTER OF HEPATOCARCINOGENESIS IN FEMALE FISCHER F344 RATS, Breast cancer research and treatment, 31(1), 1994, pp. 11-25
Tamoxifen, an antiestrogen used in the treatment of breast cancer, was
assessed for carcinogenic potential in the two-stage model of experim
ental hepatocarcinogenesis. Groups of female Fischer F344 rats were in
itiated with a non-necrogenic, subcarcinogenic dose of diethylnitrosam
ine (DEN;10 mg/kg, po) and fed tamoxifen at a concentration of 250 mg
per kg of AIN-76A diet for 6 or 15 months. The livers of these animals
exhibited an increase in size and number of altered hepatic foci comp
ared with those animals which were initiated with DEN but not exposed
to tamoxifen. This finding indicates that tamoxifen may have a carcino
genic potential in the rat liver. After 6 months of treatment, neoplas
tic nodules were observed in 3/8 rats in the DEN-initiated, tamoxifen-
treated group. In the initiated group provided with tamoxifen for 15 m
onths, neoplastic nodules were observed in 7/8 rats and hepatocellular
carcinomas in 3/8 rats. The serum level of tamoxifen in these rats wa
s 200-300 ng/ml. The ratio of tamoxifen, 4-hydroxy tamoxifen, and N-de
smethyl tamoxifen was 1:0.1:0.5-1 in the serum. When adjusted for age-
related weight increases, the serum and liver levels of tamoxifen and
its N-desmethyl metabolite did not change over the 15 months. In the r
at liver, the level of tamoxifen and its N-desmethyl metabolite was 10
-29 mu g/g liver after 6 or 15 months of chronic dietary administratio
n. The ratio of tamoxifen:4-hydroxy tamoxifen:N-desmethyl tamoxifen wa
s 1:0.1:1.3-2.3 in the liver. Therefore, the liver had 20- to 30-fold
more tamoxifen and 4-hydroxy tamoxifen and at least 100-fold more N-de
smethyl tamoxifen than the serum (assuming 1 gram of tissue is equival
ent to 1 ml of serum). These results indicate that tamoxifen is a prom
oting agent for the rat liver at serum levels found in patients given
the usual therapeutic course of tamoxifen. The high concentrations of
tamoxifen attained in the rat liver indicate that actions other than i
ts known estrogenicity for liver could contribute to its promoting act
ion. In addition, these results indicate that the pharmacodynamic diff
erences in tamoxifen metabolism in rats and humans and at low versus h
igh doses should be determined. Thus, the therapeutic indications for
tamoxifen should be balanced by the potential risk it may present as a
promoting agent in mammalian liver.